エディションの選択
First Edition BOGP (0)
Second Edition BOGP (0)
Third Edition BOGP (10)
国
オーストラリア (1)
カナダ (1)
ドイツ (2)
スペイン (1)
イギリス (3)
ノルウェー (1)
アメリカ合衆国 (2)
重点項目
Access
Advocacy (policy advocacy, lobbying)
Care Delivery/ Care pathway
Education (awareness, health promotion)
Gap analysis
Organization / System Development
Policy
Research
Other
病状
Musculoskeletal/Multiple Sclerosis (MS) (1)
Across all conditions/Other (1)
Neurology/Parkinson's Disease (1)
組織の種類
Academic Medical Center/Hospital/Practice (3)
Biotech Company (0)
Foundation (0)
Government (0)
Health technology Assessment (HTA) body (0)
NGO (0)
Insurance Company (0)
Pharmaceutical, Biotech, Medical Device Company (0)
Medical Device Company (0)
Private Public Partnership (0)
Patient Advocacy Organization (4)
Regulatory Body (0)
Pharmaceutical Company (9)
Research or Technical Organisation (0)
Research Funder (0)
Research Institution (0)
Start Up (3)
Think Tank (0)
Other (4)
ステークホルダー
Patients
Patient organisation
Healthcare professionals
Policymakers
Regulators
Payers (usually governmental or public bodies, reimbursement)
Health Technology Assessment (HTA) bodies
Pharmaceutical companies or industry (incl. Medical device and biotech companies)
Researchers (investigators and academic researchers)
Research funders
Other (please specify)
品質
Shared purpose
Respect and accessibility
Representativeness of stakeholders
Roles and responsibilities
Capacity and capabilities for engagement
Transparency in communication and documentation
Continuity and sustainability
Research and discovery
Preclinical
Clinical study phase I
Clinical study phase II
Clinical study phase III
Regulatory Review & Approval
Health Technology Assessment (HTA) activities
Post marketing
Third Edition BOGP (10)
オーストラリア (1)
Care Delivery/ Care pathway
Research or Technical Organisation (0)
Researchers (investigators and academic researchers)
Transparency in communication and documentation
Health Technology Assessment (HTA) activities
すべてクリア